Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BX Other hormone antagonists and related agents
L02BX04 Relugolix
D10888 Relugolix (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Relugolix
D10888 Relugolix (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D10888 Relugolix (JAN/USAN/INN)
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
D10888 Relugolix
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Gonadotropin-releasing hormone
GNRHR
D10888 Relugolix (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10888
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10888
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10888
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10888
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D10888